Cencora (COR) Panoramica del titolo
Cencora, Inc. si occupa dell'approvvigionamento e della distribuzione di prodotti farmaceutici negli Stati Uniti e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 5/6 |
| Crescita futura | 2/6 |
| Prestazioni passate | 5/6 |
| Salute finanziaria | 4/6 |
| Dividendi | 4/6 |
Premi
Analisi del rischio
COR Community Fair Values
Create NarrativeSee what 51 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Cencora, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$308.78 |
| Massimo di 52 settimane | US$377.54 |
| Minimo di 52 settimane | US$244.82 |
| Beta | 0.57 |
| Variazione di 1 mese | -2.91% |
| Variazione a 3 mesi | 13.82% |
| Variazione di 1 anno | 6.47% |
| Variazione a 3 anni | 66.06% |
| Variazione a 5 anni | 152.48% |
| Variazione dall'IPO | 10,356.04% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Sep 03
COR: Fair View Will Weigh Therapy Enablement Push And Nucleus Pilot Outcomes
Analysts now cite a $10 rise in their Cencora price target to $330, reflecting updated views on fair value, discount rate, revenue growth assumptions and profit margin outlooks, while still applying a similar future P/E framework. What’s in the News for Cencora Cencora’s Accelerate Pharmacy Solutions unit launched a Cell and Gene Therapy Enablement service that is designed to help health systems build and scale cell and gene therapy programs, with tailored support around financial confidence, operational readiness and scalable growth.
Aggiornamento narrativa • Aug 19
COR: Expanded Buybacks And Higher 2026 EPS Guidance Will Support Long-Term Upside
Analysts have adjusted their price target for Cencora to $372.58 from $350.58, citing updated assumptions for discount rates, profit margins, and future P/E multiples in their valuation work. What's in the News for Cencora Cencora reported a strong fiscal third quarter with revenue growth and higher adjusted diluted EPS, and raised its 2026 adjusted EPS guidance range.Recent updates
Aggiornamento narrativa • Sep 03
COR: Fair View Will Weigh Therapy Enablement Push And Nucleus Pilot Outcomes
Analysts now cite a $10 rise in their Cencora price target to $330, reflecting updated views on fair value, discount rate, revenue growth assumptions and profit margin outlooks, while still applying a similar future P/E framework. What’s in the News for Cencora Cencora’s Accelerate Pharmacy Solutions unit launched a Cell and Gene Therapy Enablement service that is designed to help health systems build and scale cell and gene therapy programs, with tailored support around financial confidence, operational readiness and scalable growth.Aggiornamento narrativa • Aug 19
COR: Expanded Buybacks And Higher 2026 EPS Guidance Will Support Long-Term Upside
Analysts have adjusted their price target for Cencora to $372.58 from $350.58, citing updated assumptions for discount rates, profit margins, and future P/E multiples in their valuation work. What's in the News for Cencora Cencora reported a strong fiscal third quarter with revenue growth and higher adjusted diluted EPS, and raised its 2026 adjusted EPS guidance range.Aggiornamento narrativa • Aug 05
COR: Fair View Will Weigh Nucleus Rollout, Cell Therapy And Legal Risk
Analysts now cite slightly firmer revenue growth, profit margin assumptions and a higher future P/E, which together support a refreshed Cencora fair value estimate increasing from $310 to $320. What’s in the News for Cencora Cencora launched a multi site pilot of its enhanced Nucleus inventory management solution for specialty physician practices, combining updated hardware and software to support medication workflow efficiency, visibility and control.Seeking Alpha • Jul 22
Cencora: Specialty Infrastructure Is Rewriting The Distributor Model
Summary Cencora (COR) is transitioning from a bulk pharmaceutical distributor to a specialty medicines infrastructure provider, targeting higher-margin, service-driven growth. Recent acquisitions of OneOncology and Retina Consultants of America are driving margin expansion, with Q2 adjusted gross profit up 15.7% and margin rising to 4.31%. Management raised FY2026 adjusted EPS guidance to $17.70–$17.90, expects $3B adjusted FCF, and targets 10–14% long-term EPS growth. Execution risks include integration of acquisitions, increased leverage, regulatory scrutiny, and high customer concentration, but specialty platform buildout is expected to deepen margins and retention. Read the full article on Seeking AlphaAggiornamento narrativa • Jul 22
COR: Fair Value View Will Weigh Nucleus Rollout And Cell Therapy Partnership
Analysts have raised their Cencora price target from $288.21 to $310.00, reflecting updated views on fair value, revenue, profit margins, and future P/E assumptions. What’s in the News for Cencora Cencora announced a multi-site pilot of its enhanced Nucleus inventory management solution for specialty physician practices, with deployment planned in phases across more than 20 practice sites.Aggiornamento narrativa • Jul 08
COR: Insider Buying And Fair Value View Will Shape Upcoming Share Performance
Analysts have nudged their price target for Cencora higher from $280.00 to about $288.21, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins, and future price-to-earnings (P/E) expectations. What’s in the News for Cencora Cencora stock moved 3.6% higher on June 23, 2026, alongside commentary that the shares are viewed as modestly undervalued relative to one intrinsic value estimate and supported by what sources describe as solid business fundamentals.Articolo di analisi • Jun 16
Cencora (COR) Stock Could Be 20% Below Fair Value On Margin Growth Narrative
Cencora (COR) stock has drawn investor attention after recent trading performance, with the share price closing at $281.43. The move comes alongside mixed short term returns and a longer multi year track record. See our latest analysis for Cencora. Recent trading puts Cencora’s 30 day share price return at 9.20%, yet the stock is still down 16.95% year to date. Longer term total shareholder returns over three and five years remain positive, suggesting recent momentum is rebuilding after a...Aggiornamento narrativa • Jun 15
COR: Buybacks And New CFO Appointment Will Support Long Term Upside
Analysts have modestly reduced their price target on Cencora to $350.58 from $356.83. This reflects slightly updated views on fair value and future P/E assumptions.Aggiornamento narrativa • Jun 01
COR: Buybacks And New CFO Will Support Long Term Upside
Analysts now estimate Cencora's fair value at $356.83 per share, down from $373.08. This change reflects updated assumptions around slightly slower revenue growth, a modestly lower profit margin outlook, and a small shift in future P/E expectations.Nuova narrativa • May 09
Specialty And AI Investments Will Shape A Stable Yet Constrained Future Trajectory
Catalysts About Cencora Cencora is a pharmaceutical services company that supports manufacturers, health systems, physician practices and pharmacies across the global pharmaceutical supply chain. What are the underlying business or industry changes driving this perspective?Aggiornamento narrativa • May 08
COR: Share Repurchases And CFO Transition Will Support Long Term Upside
Analysts now estimate Cencora’s fair value at about $373, down from roughly $403. This reflects slightly higher assumed discount rates and a lower future P/E multiple, partly offset by a marginally stronger profit margin profile in their updated models.Aggiornamento narrativa • Apr 24
COR: CFO Transition And Disciplined Buybacks Will Support Long-Term Upside
Analysts have trimmed their price target on Cencora by about $5 to reflect slightly updated assumptions around fair value, revenue growth, profit margins, and future P/E, while still viewing the shares through a similar overall framework. What's in the News Cencora plans a leadership change, with long serving Chief Financial Officer James F.Aggiornamento narrativa • Apr 08
COR: Rare Disease Collaborations And Distribution Reach Will Support Long-Term Upside
Analysts have kept their price target for Cencora steady at $407.92, citing only very small tweaks to inputs like revenue growth, profit margin and future P/E assumptions, rather than any shift in their overall view of the business. What's in the News Cencora announced that Chief Financial Officer James F.Aggiornamento narrativa • Mar 25
COR: Rare Disease Partnerships Will Support Long-Term Upside For Capital Markets Access
Analysts have adjusted their fair value estimate for Cencora to about $408 from $410, reflecting small tweaks to assumptions around the discount rate, revenue growth, profit margin, and future P/E rather than a major shift in the story. What's in the News Cencora plans for Chief Financial Officer James F.Aggiornamento narrativa • Mar 10
COR: Capital Markets And Rare-Disease Services Will Support Long-Term Upside
Analysts now place Cencora's fair value at $410.00, up from $403.79. This change reflects small adjustments to revenue growth assumptions, profit margin expectations, and future P/E estimates in their models.Aggiornamento narrativa • Feb 24
COR: 3PL Expansion And M&A Options Will Shape Balanced Long-Term Upside
Analysts have nudged their price target for Cencora higher to about $404 from roughly $400, citing refreshed assumptions around revenue growth, profitability and a modestly higher future P/E multiple. What's in the News Cencora is expanding its third party logistics capabilities in the United States and Europe, including adding NextPharma Logistics across Germany, Austria and Switzerland and planning a new 3PL facility in Italy in 2026, alongside increased cold chain capacity across its European network (company announcement).Articolo di analisi • Feb 12
Cencora (NYSE:COR) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Cencora, Inc.'s ( NYSE:COR ) recent earnings report didn't offer any surprises, with the shares unchanged over the last...Aggiornamento narrativa • Feb 08
COR: Buybacks And 3PL Expansion Will Support Long-Term Upside Potential
Analysts have nudged their projected fair value for Cencora to $399.80 from $396.80, citing updated assumptions around revenue growth, profit margins, the discount rate and a slightly lower future P/E multiple. What's in the News Cencora completed a share repurchase program totaling 4,895,419 shares, or 2.49% of shares, for US$1,118.1m under the buyback announced on May 1, 2024 (Buyback Tranche Update).Aggiornamento narrativa • Jan 23
COR: Global 3PL Expansion And Logistics Investments Will Support Long-Term Upside
Analysts have nudged their price target on Cencora higher to about US$397 from roughly US$388. This reflects refreshed assumptions on revenue growth, profit margins and future P/E levels in their models.Aggiornamento narrativa • Jan 09
COR: Global 3PL Buildout And Higher Dividend Will Support Long-Term Upside
Analysts have nudged their price target on Cencora higher to about $388, citing slightly lower modeled revenue growth, a modestly stronger profit margin, and a small uptick in assumed future P/E as key drivers of the updated view. What's in the News Cencora announced investments to expand its third party logistics capabilities in the United States and Europe, including broader specialty logistics services for pharmaceutical companies worldwide.Aggiornamento narrativa • Dec 16
COR: Global 3PL Expansion And Dividend Increases Will Offset Goodwill Impairment Risks
Analysts have slightly raised their price target on Cencora, increasing fair value by about 1.8 dollars per share as they factor in marginally stronger projected revenue growth, a modestly higher long term profit margin, and a steady future earnings multiple. What's in the News Cencora is making major investments to expand its third party logistics network, including a new 500,000 square foot 3PL facility in Texas by 2028 and a tripling of ultra low and cryogenic storage capacity in the United States, to support growing demand for specialty medicines such as cell and gene therapies (company announcement).Aggiornamento narrativa • Dec 02
COR: Automated Distribution Expansion And Margins Will Balance Storage And Dividend Risks
Analysts have modestly raised their price target for Cencora, increasing the estimated fair value by $2.71 to $384.79. This adjustment is based on slight improvements in profit margin expectations and valuation multiples.Aggiornamento narrativa • Nov 18
COR: Automated Expansion And Margin Gains Will Offset Ongoing Legal Risks
Analysts have raised their price target for Cencora, increasing the estimated fair value from $338.29 to $382.07. They cite strengthened profit margin expectations, even though there is a slightly higher discount rate and moderated revenue growth forecasts.Aggiornamento narrativa • Nov 04
COR: Ongoing Litigation Settlement And Buybacks Will Shape Healthcare Delivery Evolution
Analysts have raised their price target for Cencora by $5 to $338.29. They cite updated forecasts for slightly lower near-term revenue growth, but a stronger overall fair value assessment.Aggiornamento narrativa • Sep 04
Digital Infrastructure And Specialty Services Will Redefine Healthcare Delivery
With both Cencora’s net profit margin and consensus revenue growth forecasts holding steady, analysts have maintained their price target unchanged at $333.29. What's in the News Cencora completed the repurchase of 4,895,419 shares (2.49% of shares outstanding) for $1,118.1 million under its buyback program announced in May 2024; no shares were repurchased from April to June 2025.Rendimenti per gli azionisti
| COR | US Healthcare | US Mercato | |
|---|---|---|---|
| 7D | -4.0% | -1.7% | -0.2% |
| 1Y | 6.5% | 16.9% | 12.1% |
Ritorno vs Industria: COR ha avuto una performance inferiore rispetto al US Healthcare che ha registrato un rendimento 16.9 % nell'ultimo anno.
Rendimento vs Mercato: COR ha avuto una performance inferiore al mercato US che ha registrato un rendimento 12.1 % nell'ultimo anno.
Volatilità dei prezzi
| COR volatility | |
|---|---|
| COR Average Weekly Movement | 3.9% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 2.9% |
Prezzo delle azioni stabile: COR non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 4% ) di COR è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1871 | 49,000 | Bob Mauch | www.cencora.com |
Cencora, Inc. fornisce e distribuisce prodotti farmaceutici negli Stati Uniti e a livello internazionale. Il segmento U.S. Il segmento Healthcare Solutions distribuisce prodotti farmaceutici generici e iniettabili, prodotti sanitari da banco, forniture e attrezzature per l'assistenza sanitaria a domicilio e servizi correlati a ospedali per acuti e sistemi sanitari, farmacie al dettaglio indipendenti e di catena, farmacie per corrispondenza, cliniche mediche, farmacie per l'assistenza a lungo termine e per siti alternativi e altri clienti; distribuisce plasma e altri prodotti ematici, vaccini e altri prodotti farmaceutici speciali; fornisce servizi di consulenza per la gestione delle farmacie, del personale e di altro tipo; software per la gestione delle forniture a fornitori di servizi sanitari istituzionali e al dettaglio; soluzioni di confezionamento a fornitori di servizi sanitari istituzionali e al dettaglio; servizi di supporto per studi clinici, post-approvazione di prodotti e commercializzazione; analisi dei dati, ricerca sui risultati e altri servizi per produttori di biotecnologie e prodotti farmaceutici; prodotti farmaceutici, vaccini, parassiticidi, diagnostici, ingredienti per micro mangimi e altri prodotti per i mercati degli animali da compagnia e da produzione; servizi di forza vendita per i produttori; e offre altri servizi a medici specializzati in vari stati patologici, come l'oncologia, e ad altri fornitori di servizi sanitari, tra cui ospedali e cliniche di dialisi.
Cencora, Inc. Riepilogo dei fondamenti
| COR statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$58.92b |
| Utili (TTM) | US$2.62b |
| Ricavi(TTM) | US$332.77b |
22.4x
Rapporto P/E0.2x
Rapporto P/SCOR è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| COR Conto economico (TTM) | |
|---|---|
| Ricavi | US$332.77b |
| Costo del fatturato | US$319.59b |
| Profitto lordo | US$13.18b |
| Altre spese | US$10.56b |
| Utili | US$2.62b |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 13.75 |
| Margine lordo | 3.96% |
| Margine di profitto netto | 0.79% |
| Rapporto debito/patrimonio netto | 361.9% |
Come si è comportato COR nel lungo periodo?
Vedi performance storica e confrontoDividendi
0.8%
Rendimento attuale del dividendo17%
Rapporto di remunerazioneAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/20 14:44 |
| Prezzo dell'azione a fine giornata | 2026/09/18 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/09/30 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Cencora, Inc. è coperta da 31 analisti. 13 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| David Toung | Argus Research Company |
| Eric Coldwell | Baird |
| Glen Santangelo | Barclays |